Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138, Naples, Italy.
Department of Medicine and Health Sciences "V. Tiberio", University of Molise, Via Francesco De Sanctis 1, Campobasso, Italy.
Med Oncol. 2020 Apr 9;37(5):45. doi: 10.1007/s12032-020-01360-2.
Cholangiocarcinoma (CC) accounts for about 3% of the gastrointestinal and 10-25% of all hepatobiliary malignancies. It arises from the epithelium of the bile duct and it can be classified in intrahaepatic (ICC), perihilar (PCC) and distal (DCC) cholangiocarcinoma, depending on the anatomical location. About 50-60% of the cases are PCC. Early detection is very difficult for the lack of symptoms, and most of the patients are not resectable at the time of diagnosis. IRE is a non-thermal ablation technique that determines cellular apoptosis by electrical impulses without involving extracellular matrix like MW or RF ablation (MWA and RFA). The aim of our study is to demonstrate the safety, feasibility and efficacy of this procedure in the treatment of cholangiocarcinoma according to our experience. From 2015 to 2019, fifteen patients with unre-sectable perhilar and intrahepatic colangiocarcinoma (7 female and 8 male, mean age 69.2) were referred to our department to be enrolled in our prospective study that was approved by local Ethical Committee. Eight lesions were defined iCC and seven of them pCC. Six patients had biliary STENT and four external percutaneous transhepatic biliary drainage (PTBD). The IRE procedure was performed to expert radiologist (G.B.) under CT guidance using the Nanoknife IRE device (Angiodynamics, Queensbury, NY). The data before and after treatment were compared using Wilcoxon Rank Test and the survival outcome was evaluated using Kaplan Meyer Test. All procedures performed under CT guidance have been successfully completed. Treated lesions were located seven perhilar and eight intrahepatic sites and showed a mean volume 66.3 (SD 70.9; IC ranged from 5.57 to 267.20 cm). No major complications were observed. From 30 to 90 days, the mortality rate was around 0%. Progression of the disease in all cases were not observed. Only one patient was reported increase of the Ca19-9 without sign of pancreatitis and bile obstruction. The imaging follow-up showed the local disease control with a decrease of the entire volume of the lesion and a further reduction of the densitometric values. From the comparison between the mean volumes for each group (before and after treatment), the Wilcoxon Rank test demonstrated the statistical significant difference with a p value < 0.01. On the contrary, it is believed that this results encouraging in considering the IRE procedure the safe, feasible and effective method in the treatment of the CC.
胆管癌(CC)约占胃肠道的 3%,占所有肝胆恶性肿瘤的 10-25%。它起源于胆管上皮,可以根据解剖位置分为肝内(ICC)、肝门周围(PCC)和远端(DCC)胆管癌。大约 50-60%的病例为 PCC。由于缺乏症状,早期检测非常困难,大多数患者在诊断时无法进行切除。IRE 是一种非热消融技术,通过电脉冲而不是像 MW 或 RF 消融(MWA 和 RFA)那样涉及细胞外基质来确定细胞凋亡。我们的研究目的是根据我们的经验证明该程序在治疗胆管癌方面的安全性、可行性和疗效。
从 2015 年到 2019 年,15 名不可切除的肝门周围和肝内胆管癌患者(7 名女性和 8 名男性,平均年龄 69.2 岁)被转介到我们部门参加我们的前瞻性研究,该研究得到了当地伦理委员会的批准。
8 个病变被定义为 iCC,其中 7 个为 pCC。6 例患者有胆道支架,4 例有经皮经肝胆道引流(PTBD)。IRE 程序由放射科专家(GB)在 CT 引导下使用 Nanoknife IRE 设备(Angiodynamics,Queensbury,NY)进行。使用 Wilcoxon 秩检验比较治疗前后的数据,使用 Kaplan Meyer 检验评估生存结果。
在 CT 引导下进行的所有程序均已成功完成。治疗部位位于 7 个肝门周围和 8 个肝内部位,平均体积为 66.3(SD 70.9;IC 范围为 5.57 至 267.20 cm)。未观察到主要并发症。
在 30 至 90 天内,死亡率约为 0%。所有病例均未观察到疾病进展。只有 1 例患者报告 CA19-9 升高,但无胰腺炎和胆汁淤积迹象。影像学随访显示局部疾病控制,病变整体体积减少,密度值进一步降低。
从每组(治疗前后)的平均体积比较来看,Wilcoxon 秩检验显示具有统计学意义(p 值<0.01)。相反,考虑到 IRE 程序是治疗 CC 的安全、可行和有效的方法,这些结果令人鼓舞。